The US Food and Drug Administration will now require antibody test makers to promptly seek FDA authorization, as the agency aims to rein in unproven and fraudulent tests that have flooded the market. The new policy, announced Monday, requires commercial manufacturers to submit emergency authorization requests, along with validation data for their antibody tests, within 10 business days. The FDA is also setting specific performance recommendations for all test developers.